文献速递MDS 与骨髓增殖性肿瘤

高危MDS对阿扎胞苷联合来那度胺的应答受三个肌醇特异性基因簇的基线及获得性突变影响

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.
PubMed 文献 · Leukemia · 2019-02-20

44例高危MDS患者接受阿扎胞苷联合来那度胺治疗,基线及治疗中行突变分析。34例可评估应答,总应答率76.25%(26/34)。所有早期失去应答及从未应答者均获得PIK3CD、AKT3、PLCG2三个点突变,该突变簇与更短OS、LFS及应答持续时间显著相关。

要点

  • 34例可评估患者中总应答率76.25%(26/34),17例持久应答,9例早期失去应答,8例从未应答。
  • 最常见突变为ASXL1、TET2、RUNX1和SRSF2。
  • 所有早期失去应答及从未应答者均获得PIK3CD D133E、AKT3 D280G、PLCG2 Q548R三个点突变。

核心结论

  • 影响3个肌醇特异性基因的共同突变簇与高危MDS对阿扎胞苷联合来那度胺治疗失去应答显著相关。
  • 需进一步研究以确认这些数据并分析该3基因簇的功能作用。

研究设计与样本

  • 44例高危MDS患者接受阿扎胞苷联合来那度胺治疗,基线及治疗期间行突变分析。
  • 结果与临床结局、总生存(OS)、无白血病生存(LFS)及治疗应答进行相关性分析。

主要发现

  • 34/44例可评估应答,总应答率76.25%(26/34):17例持久应答,9例早期失去应答,8例从未应答。
  • 最常见突变为ASXL1、TET2、RUNX1和SRSF2。
  • 所有早期失去应答及从未应答者均在治疗期间获得相同3个点突变:PIK3CD(D133E)、AKT3(D280G)、PLCG2(Q548R)。
  • Kaplan-Meier分析显示该突变簇与更短OS、LFS及应答持续时间显著相关。

局限性

  • 需进一步研究以确认这些数据并分析该3基因簇的功能作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlated to clinical outcome, overall survival (OS), leukemia-free-survival (LFS) and response to therapy. Collectively, 34/44 patients were considered evaluable for response, with an overall response rate of 76.25% (26/34 cases): 17 patients showed a durable response, 9 patients early lost response and 8 patients never responded. The most frequently mutated genes were ASXL1, TET2, RUNX1, and SRSF2. All patients early losing response, as well as cases never responding, acquired the same 3 point mutations during therapy, affecting respectively PIK3CD (D133E), AKT3 (D280G), and PLCG2 (Q548R) genes, that regulate cell proliferation and differentiation. Moreover, Kaplan-Meier analyses revealed that this mutated cluster was significantly associated with a shorter OS, LFS, and duration of response. All in all, a common mutated cluster affecting 3 inositide-specific genes is significantly associated with loss of response to azacitidine and lenalidomide therapy in higher risk MDS. Further studies are warranted to confirm these data and to further analyze the functional role of this 3-gene cluster.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Follo MY, Pellagatti A, Armstrong RN, et al. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia. 2019. PMID: 30787430. doi:10.1038/s41375-019-0416-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。